Last $677.80 MXN
Change Today 0.00 / 0.00%
Volume 0.0
SNYN On Other Exchanges
Symbol
Exchange
EN Paris
EN Paris
New York
OTC US
BrsaItaliana
Mexico
Frankfurt
Frankfurt
NASDAQ GM
As of 4:09 PM 07/8/14 All times are local (Market data is delayed by at least 15 minutes).

sanofi-adr (SNYN) Snapshot

Open
$677.92
Previous Close
$677.80
Day High
$677.92
Day Low
$677.80
52 Week High
05/5/14 - $710.59
52 Week Low
02/6/14 - $626.75
Market Cap
1.8T
Average Volume 10 Days
2.4K
EPS TTM
--
Shares Outstanding
2.6B
EX-Date
05/7/14
P/E TM
--
Dividend
$1.91
Dividend Yield
3.66%
Current Stock Chart for SANOFI-ADR (SNYN)

sanofi-adr (SNYN) Details

Sanofi researches, develops, manufactures, and markets healthcare products. The company operates in three segments: Pharmaceuticals, Human Vaccines, and Animal Health. Its products include Lantus and Apidra analogs of human insulin; Insuman human insulin solutions and suspensions; Amaryl, a sulfonylurea; BGStar, iBGStar, and MyStar Extra blood glucose meters; enzyme replacement therapies, such as Cerezyme for Gaucher disease, Fabrazyme for Fabry, and Myozyme/Lumizyme for Pompe disease; Aldurazyme, for mucopolysaccharidosis Type I; Aubagio, a immunomodulator for multiple sclerosis; Taxotere, a taxane derivative for cancers; Eloxatine for colorectal cancer; and Jevtana for prostate cancer. The company’s products also comprise thrombosis medicines, such as Plavix anti-platelet agent for atherothrombotic conditions and Lovenox to prevent and treat deep vein thrombosis; and cardiovascular medicines, including Multaq anti-arrhythmic agent and Aprovel/CoAprovel for hypertension treatments. It also offers Renagel/Renvela for patients with chronic kidney disease on dialysis to treat high phosphorus levels; Synvisc and Synvisc-One viscosupplements to treat pain associated with osteoarthritis; and pediatric and influenza, adult and adolescent booster, meningitis and pneumonia, and travel and endemics vaccines. In addition, the company provides pharmaceuticals and vaccines used by veterinarians, farmers, and pet owners; consumer health care products; and generic medicines. Sanofi distributes its products through its sales force, as well as through physicians, pharmacies, hospitals, distributors, veterinaries, chemists, and wholesalers. It has strategic alliances with Bristol-Myers Squibb, Regeneron, Warner Chilcott, Regulus Therapeutics Inc., and Medtronic, Inc., as well as a strategic collaboration with UCB S.A. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1970 and is headquartered in Paris, France.

112,128 Employees
Last Reported Date: 03/7/14
Founded in 1970

sanofi-adr (SNYN) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: €3.0M
Compensation as of Fiscal Year 2013.

sanofi-adr (SNYN) Key Developments

FDA Accepts Sanofi's New Drug Application for Basal Insulin Toujeo(R)

Sanofi announced that the U.S. Food and Drug Administration has accepted for review the company's New Drug Application (NDA) for Toujeo(R) (insulin glargine [rDNA origin] injection, 300 U/mL), an investigational basal insulin. The acceptance of the NDA follows the acceptance of the marketing authorization dossier for Toujeo by the European Medicines Agency (EMA) for EU countries on May 27, 2014.

Sanofi to Increase Output Capacity in Mexico

Sanofi plans to increase production and exports in Mexico. Sanofi wants to use Mexico as a production and exports hub for the rest of Latin America, focusing on the firm's vaccines portfolio. Local production will increase from its existing level of 40 million to 50 million doses of the company's vaccine products. Sanofi also provides influenza vaccines to the Secretariat for Health in Mexico. This body will receive 35 million doses this year, up from 22 million in 2013 and 12 million in 2012.

Sanofi and Medtronic, Inc. Signs Memorandum of Understanding to Develop Diabetes Management Solutions

Sanofi and Medtronic, Inc. announced that it have signed a memorandum of understanding, or MoU, to enter into a strategic alliance for management of diabetes. The alliance will initially focus on two key priorities: the development of drug-device combinations and delivery of care management services to improve adherence, simplify insulin treatment, and help people with diabetes better manage their condition. The alliance will be structured as an open-innovation model, leveraging the capabilities, as well as the human and financial resources, of both companies. Based on the success of the two initial priorities, the companies may explore other areas for potential collaboration. The alliance will pair Sanofi's extensive insulin portfolio and drug development expertise with Medtronic's expertise in insulin pumps and continuous glucose monitoring. One of the priorities of the alliance will be to deliver novel drug-device combinations, including new form factors that are affordable, convenient and easy to use to increase therapy adherence and deliver better outcomes. These efforts will focus on improving the management of Type 2 diabetes, especially for people who cannot achieve glucose control even with multiple daily injections of insulin. Care management services, another priority area for collaboration, will be delivered through a program designed to guide people with Type 2 diabetes who are failing to achieve disease control on oral therapies through the initiation phase of insulin treatment. Insulin initiation can be challenging as a high number of patients drop insulin treatment in this early phase. As world leaders in complementary segments of diabetes care, Sanofi and Medtronic already have an agreement in place serving specific Type 1 diabetes patients in Europe with an implantable insulin delivery system, and intend to add this project and additional innovative projects to the alliance. Implementation of the alliance is subject to the negotiation and execution of a definitive agreement between the companies.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SNYN:MM $677.80 MXN 0.00

SNYN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bayer AG €103.28 EUR -0.08
Gilead Sciences Inc $88.68 USD +1.57
GlaxoSmithKline PLC 1,557 GBp +5.50
Merck & Co Inc $58.55 USD +0.38
Novo Nordisk A/S kr247.20 DKK -1.70
View Industry Companies
 

Industry Analysis

SNYN

Industry Average

Valuation SNYN Industry Range
Price/Earnings 26.5x
Price/Sales 3.0x
Price/Book 1.7x
Price/Cash Flow 15.0x
TEV/Sales 2.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANOFI-ADR, please visit www.sanofi-aventis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.